Pharma Business - September 30, 2021
Sprint Bioscience starts marketing additional cancer drug program
Sprint Bioscience has announced that it is starting to market the DISA program to potential partners and, following a series of research advances, reveals the cancer drug program’s target protein, TREX1. The goal of the program, currently in the preclinical phase, is to develop drugs that inhibit the protein TREX1 in order to enhance the […]
Biotech Business - September 14, 2021
Sprint Bioscience adds new cancer drug program to its pipeline
Sprint Bioscience is broadening its pipeline with an additional drug program for the treatment of solid tumors. The program goes by the program name NIMA and aims to develop drugs to inhibit a naturally occurring protein that is associated with poor survival in several different forms of cancer, states the company. “We have once again […]
Pharma Business - May 13, 2020
Sprint announces target protein for VADA project
Sprint Bioscience has announced that after a series of preclinical research advances in the VADA project, it has been decided to publish the project’s target protein. The goal is to develop drug substances that inhibit the protein vaccinia-related kinase 1 (VRK1) in order to enhance the effects of immuno-oncology therapy, radiation therapy and chemotherapy. The […]
Drug Development Pharma - May 5, 2020
Sprint Bioscience announces positive data
Sprint Bioscience has announced that a new scientific study with positive data concerning the company’s lead compound SB02024 has been published in Science Advances. The research results show that SB02024 activates the immune system in tumors in malignant melanoma and colorectal cancer. Sprint Bioscience is thus first in the world to demonstrate that inhibition of […]
Agreement - August 8, 2016
Sprint Bioscience signs licence agreement
Sprint Bioscience and the US drug development company Petra Pharma Corporation have entered into a collaboration and license agreement for the research, development, and commercialization of Sprint Bioscience’s PIP4K2a program targeting tumor metabolism. Under the agreement, Sprint Bioscience licenses a PIP4k2a inhibitor program targeting tumor metabolism to the US company. Subsequently, the US company will […]
Pharma Business - September 3, 2013
Sprint Bioscience ready for the next step
The Uppsala-based company has been named Alumni company at Uppsala Innovation Centre. Sprint Bioscience was accepted to the incubator Uppsala Innovation Centre’s (UIC) program when its product idea and business plan was just in its infancy. Today the company has finished the program at UIC and has been named Alumni company, meaning they have the […]
